Spurned by Ab­b­Vie, Abl­ynx wins an­oth­er Big Phar­ma part­ner of­fer­ing a block­buster prize for suc­cess

Sanofi CEO Olivi­er Brandi­court (left), flanked by CFO Jerome Con­t­a­mine, speaks dur­ing a Feb­ru­ary 2017 com­pa­ny pre­sen­ta­tion get­ty

Nine months af­ter Ab­b­Vie dealt Abl­ynx a blow by walk­ing away from a messy rheuma­toid arthri­tis drug it was part­nered on, the Bel­gian biotech has come back and added an­oth­er Big Phar­ma com­pa­ny to its list of part­ners for its Nanobody plat­form tech. And this one is dan­gling a trea­sure trove of mile­stone pay­ments if its re­searchers can turn in a block­buster per­for­mance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER